DYNE-101 + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myotonic Dystrophy Type 1 (DM1)
Conditions
Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease, Steinert
Trial Timeline
Apr 1, 2026 → Jan 1, 2029
NCT ID
NCT07486934About DYNE-101 + Placebo
DYNE-101 + Placebo is a phase 3 stage product being developed by Dyne Therapeutics for Myotonic Dystrophy Type 1 (DM1). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07486934. Target conditions include Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy.
What happened to similar drugs?
0 of 1 similar drugs in Myotonic Dystrophy Type 1 (DM1) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07486934 | Phase 3 | Recruiting |
| NCT05481879 | Phase 1/2 | Recruiting |
Competing Products
16 competing products in Myotonic Dystrophy Type 1 (DM1)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 20 |
| Tideglusib | AMO Pharma | Phase 2 | 25 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 28 |
| Tideglusib | AMO Pharma | Phase 2/3 | 35 |
| VX-670 | Vertex Pharmaceuticals | Phase 2 | 42 |
| VX-670 + Placebo | Vertex Pharmaceuticals | Phase 1/2 | 39 |
| SAR446268 | Sanofi | Phase 1/2 | 39 |
| rhIGF-I/rhIGFBP-3 + placebo | Insmed | Phase 2 | 32 |
| IONIS-DMPKRx + Placebo | Ionis Pharmaceuticals | Phase 1/2 | 29 |
| Del-desiran (AOC 1001) | Avidity Biosciences | Phase 3 | 44 |
| ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) Injection | Arrowhead Pharmaceuticals | Phase 1/2 | 36 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 1/2 | 33 |
| Pitolisant Oral Tablet + Placebo oral tablet | Harmony Biosciences | Phase 2 | 29 |
| PGN-EDODM1 | PepGen | Phase 2 | 32 |
| PGN-EDODM1 | PepGen | Phase 2 | 32 |
| PGN-EDODM1 for infusion | PepGen | Phase 1 | 19 |